AstraZeneca Nabs CinCor’s Hypertension Asset In $1.3bn Acquisition

Potential Combination With Farxiga

The UK major is acquiring CinCor in a deal that could be worth up to $1.8bn, in return getting hold of its Phase II hypertension candidate, baxdrostat, which offers combination potential with Farxiga.    

Heart made out of red puzzle pieces with one piece missing
CinCor's Asset Circumvents The Typical Cortisol Reduction Problem • Source: Shutterstock

AstraZeneca PLC is acquiring CinCor Pharma, Inc. for $1.3bn upfront in a bid to bolster its cardiorenal pipeline through the addition of a next-generation aldosterone synthase inhibitor (ASI) asset that could pair well with Farxiga. The company announced the deal on the opening day of the J.P. Morgan Healthcare Conference on 9 January. 

The upfront payment comprises a tender offer to buy all of CinCor’s outstanding shares for $26 each, representing a 121%...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.